TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31575509
Drug: Pamrevlumab 30
Normalized name: Pamrevlumab
DrugBank: Pamrevlumab (DB14952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamrevlumab 30 mg/kg every 3 weeks for 48 weeks (16 infusions)
Study: 26343698
Drug: PUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA supplementation (1.3 g of PUFA and 10 mg of vitamin E daily for 12 weeks)
Study: 26343698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (11 mg of vitamin E daily for 12 weeks)
Study: 16340949
Drug: Oligofructose (OFS)
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (OFS) 8 g twice daily (16 g/day)
Study: 16340949
Drug: Placebo (dextrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrine maltose (DM)) 8 g twice daily (16 g/day)
Study: 11006176
Drug: Cyclical sequential
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical sequential norethisterone (NET)-based HRT with continuous 2 mg oral oestradiol valerate for three cycles
Study: 11006176
Drug: Trimegestone-based HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone-based HRT regimens (0.05, 0.1, 0.25 and 0.5 mg/day from day 15-28 for six treatment cycles)
Study: 9248777
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of mirtazapine in the fasting state
Study: 9248777
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of mirtazapine after a high-fat meal
Study: 740581
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with oestrogen and progestogen
Study: 28724186
Drug: 4% topical
Normalized name: BPO 4% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% topical formulation of InsP6 applied once a day
Study: 28724186
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid gel (control)
Study: 28724186
Drug: 4% topical
Normalized name: BPO 4% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% topical formulation of InsP6
Study: 17888460
Drug: GABA‐A/benzodiazepine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA‐A/benzodiazepine receptor inverse agonist selective for the alpha5 subtype (a5IA)
Study: 11771983
Drug: Scopolamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3 mg, i.v.)
Study: 11771983
Drug: Glycopyrrolate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.2 mg, i.v.)
Study: 8385525
Drug: Lisinopril 10mg
Normalized name: LISINOPRIL 10MG TAB
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril 10mg once daily
Study: 8385525
Drug: Enalapril 10mg
Normalized name: enalapril 10 MG
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril 10mg once daily
Study: 25231730
Drug: High-Ca group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Ca group (actual Ca intake: 1243 mg/d)
Study: 25231730
Drug: Medium-Ca group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-Ca group (actual Ca intake: 985 mg/d)
Study: 27980462
Drug: Edoxaban 30
Normalized name: edoxaban 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 30 mg QD
Study: 22664798
Drug: Edoxaban 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 45 mg QD
Study: 22664798
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg QD
Study: 19520690
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab plus PDT using a light dose of 25 J/cm2 (group 1)
Study: 19520690
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab plus PDT using a light dose of 12 J/cm2 (group 2)
Study: 14963719
Drug: Betamethasone solution
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone solution (0.4 mg/ml)
Study: 7271298
Drug: Chemotherapy (2-year
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (2-year course)
Study: 23435159
Drug: Basal-bolus regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus regimen with glargine once daily and glulisine before meals
Study: 26459273
Drug: Premixed human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed human insulin (30% regular insulin and 70% NPH insulin) twice daily
Study: 26459273
Drug: Premixed human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed human insulin
Study: 21795430
Drug: Calcium doses
Normalized name: Docusate Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium doses ≥1000 mg
Study: 21795430
Drug: Calcium dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dose of 800 mg
Study: 2498565
Drug: Continuous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous regimen of propranolol (4 or 3 times daily)
Study: 2498565
Drug: Intermittent regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent regimen of propranolol (twice daily)
Study: 2498565
Drug: Twice-daily regimen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimen of propranolol
Study: 2498565
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily doses of propranolol
Study: 27930613
Drug: Community empowerment-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community empowerment-based combination HIV prevention model (Project Shikamana)
Study: 26231305
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg administered monthly
Study: 26231305
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg administered as needed (PRN) after 3 monthly loading doses
Study: 24597260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without any analgesic measurements
Study: 21406193
Drug: Ubiquinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (100 mg/day)
Study: 21406193
Drug: Ubiquinone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone (100 mg/day)
Study: 14662586
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with ablation of the avascular retina
Study: 14662586
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (control eye)
Study: 10960936
Drug: Regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapy (physical therapy and occupational therapy)
Study: 1467105
Drug: Closed-loop computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop computer control of an infusion of a 5:1 mixture of trimetaphan camsylate (TMP) and sodium nitroprusside (SNP)
Study: 6086866
Drug: VZIG (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: VZIG (standard doses)
Study: 6086866
Drug: IGIV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV at 4 ml/kg every 4 weeks for four doses
Study: 6086866
Drug: IGIV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV at 6 ml/kg every 6 weeks for two to four doses
Study: 6086866
Drug: IGIV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV at 4 ml/kg
Study: 6086866
Drug: IGIV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV at 6 ml/kg
Study: 30922731
Drug: Lenvatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib plus pembrolizumab (20 mg oral lenvatinib daily plus 200 mg intravenous pembrolizumab every 3 weeks)
Study: 26488145
Drug: Arthrocentesis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis group (aspiration before hyaluronan injection)
Study: 26488145
Drug: Nonarthrocentesis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonarthrocentesis group (no aspiration before hyaluronan injection)
Study: 20362976
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) based on exposure and mindfulness exercises delivered via the Internet.
Study: 18847622
Drug: School nurse
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School nurse supervision of glucose and insulin-dose adjustment (3-month intervention)
Study: 16212578
Drug: sub-antimicrobial doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sub-antimicrobial doxycycline (20 mg, bid)
Study: 11840077
Drug: Standard titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titer (50% tissue culture‐infective dose, 103.8) Schwarz measles vaccine after meningococcal vaccine
Study: 11840077
Drug: Increased titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased titer (10(4.7) PFU) Edmonston‐Zagreb measles vaccine followed by meningococcal vaccine
Study: 11840077
Drug: Increased titer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased titer (10(4.7) PFU) Connaught vaccine followed by standard titer Schwarz measles vaccine
Study: 1981019
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg alone
Study: 1981019
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg with rifampicin 600 mg once daily
Study: 1981019
Drug: Tertatolol 5
Normalized name: tertatolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertatolol 5 mg with ranitidine 150 mg twice daily
Study: 31185906
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral paracetamol
Study: 31185906
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg oral paracetamol
Study: 26194675
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy (HFRT)
Study: 26194675
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy (STRT)
Study: 20708287
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg (slow-release)
Study: 19213787
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg intravenously)
Study: 17093248
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg on days 0 and 4)
Study: 16824149
Drug: Daclizumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (50 mg on days 1 and 14)
Study: 10831476
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment of bipolar I disorder with anxiety symptoms
Study: 10831476
Drug: Acute treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute treatment of bipolar I disorder without anxiety symptoms
Study: 9118516
Drug: Prostacyclin (epoprostenol)
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (epoprostenol) infusion for 12 weeks in addition to conventional therapy (n = 41)
Study: 9118516
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone for 12 weeks (n = 40)
Study: 8472628
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GL‐G injection (intramuscularly)
Study: 8472628
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GL‐G injection (intravenously)
Study: 8472628
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg GL‐G injection
Study: 3525176
Drug: Intermediate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose methotrexate (ID-MTX) and prednisone (PRED)
Study: 31936495
Drug: Biophysical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biophysical therapy
Study: 29570546
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) sessions
Study: 24726166
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with optimal medical therapy
Study: 24726166
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone (MED)
Study: 18753099
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (n = 60)
Study: 16293352
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg/day as a single dose)
Study: 16698134
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (120 mg/day)
Study: 8143832
Drug: Oral indomethacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral indomethacin, 50 mg t.d.s. for 3 days
Study: 26609122
Drug: Trauma-Focused (TF)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-Focused (TF) treatment (8 sessions prolonged exposure or eye movement desensitization)
Study: 21911136
Drug: Daclizumab (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (54 patients, group D) plus cyclosporine (CsA), mycophenolate mofetil and steroids
Study: 21911136
Drug: Thymoglobulin (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (55 patients, group T) plus cyclosporine (CsA), mycophenolate mofetil and steroids
Study: 16966688
Drug: oblimersen sodium
Normalized name: oblimersen
DrugBank: Oblimersen (DB13811)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oblimersen sodium plus dacarbazine (1,000 mg/m2)
Study: 14767414
Drug: General program
Approvals — FDA: no, EMA: no, PMDA: no
Description: General program of psychomotor therapy (GPMT)
Study: 11517472
Drug: Semax (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semax (12 mg for moderate severity, 18 mg for severe strokes, treatment course of 5 to 10 days)
Study: 8474482
Drug: Levodopa therapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa therapy after apomorphine test
Study: 3779035
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g doses four times a day for 2 days prior to and during the study)
Study: 3779035
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg single oral dose)
Study: 28714788
Drug: Deep Oscillation
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Oscillation Therapy (DOT)
Study: 28054902
Drug: Novel goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel goal-directed hemodynamic optimization therapy (GDHOT) based on major vasopressor and inotropic therapy (SG)
Study: 28054902
Drug: Standard goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard goal-directed hemodynamic optimization therapy (GDHOT) (CG)
Study: 24953368
Drug: Tissue-selecting therapy
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-selecting therapy (TST)
Study: 12960371
Drug: NCX-4016 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX-4016 (800 mg twice a day)
Study: 12960371
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice a day) with aspirin
Study: 12960371
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg twice a day) with NCX-4016
Study: 12960371
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and NCX-4016
Study: 8694619
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg methylprednisolone in the pump prime (group II)
Study: 8694619
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid (group I)
Study: 1751270
Drug: Extradural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural analgesia with continuous infusion of 0.25% bupivacaine with fentanyl
Study: 1751270
Drug: Extradural analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural analgesia with continuous infusion of 0.25% bupivacaine without fentanyl
Study: 1751270
Drug: Parenteral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioid analgesia
Study: 30425008
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication review (CMR) focused on personal goals using Goal Attainment Scaling (GAS)
Study: 30425008
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of recommendations for GAS-related drug-related problems (DRPs)
Study: 29560909
Drug: Accelerated intermittent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated intermittent theta burst stimulation (aiTBS) treatment, 20 iTBS sessions applied to the left dorsolateral prefrontal cortex (5 daily sessions spread over 4 days)
Study: 27333958
Drug: Aster spathulifolius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aster spathulifolius Maxim extract (700 mg/d of ASE)
Study: 25234526
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg and Celecoxib 400 mg (experimental group)
Study: 25234526
Drug: Lactose powder
Normalized name: Lactose Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder 2 g (placebo group)
Study: 19384168
Drug: Standard-dose CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CsA
Study: 19384168
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of CsA
Study: 19384168
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with serum creatinine ≤ 1.5 mg/mL
Study: 17587625
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injection plus therapeutic exercise
Study: 15986724
Drug: Functional Swallowing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Swallowing Therapy (FST)
Study: 12147313
Drug: 1000 IU/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU/h intravenous unfractionated heparin (UFH), n=70
Study: 12147313
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral aspirin, n=97
Study: 12013486
Drug: Low-sodium mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium mineral water (sodium, chloride and bicarbonate < 0.02 mmol/l)
Study: 12013486
Drug: Sodium bicarbonate-rich
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate-rich mineral water (sodium 39.3 mmol/l, chloride 6.5 mmol/l, bicarbonate 48.8 mmol/l)
Study: 12013486
Drug: Sodium chloride-rich
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride-rich mineral water (sodium 84.5 mmol/l, chloride 63.7 mmol/l, bicarbonate 21.9 mmol/l)
Study: 1601536
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum plus psychological treatment (NG-PT)
Study: 1601536
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum plus psychological treatment and partner support (NG-PT-PS)
Study: 25528834
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) escitalopram
Study: 20478877
Drug: Medication switch
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switch alone (alternate SSRI or venlafaxine)
Study: 20478877
Drug: Medication switch
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switch plus cognitive‐behavioral therapy (CBT)
Study: 19085343
Drug: Aliskiren/HCT 300/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/HCT 300/12.5 mg
Study: 19085343
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg monotherapy
Study: 12881590
Drug: Oral carbenoxolone
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to patients with ocular hypertension.
Study: 12881590
Drug: Oral carbenoxolone
Normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbenoxolone (CBX), an inhibitor of 11beta‐HSD, administered to healthy volunteers.
Study: 10320172
Drug: Intraperitoneal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal lidocaine (0.5% in 80 mL)
Study: 10320172
Drug: Both IM
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IM morphine (10 mg in 1 mL) and intraperitoneal lidocaine (0.5% in 80 mL)
Study: 10320172
Drug: IM morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM morphine (10 mg in 1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)
Study: 10320172
Drug: IM isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IM isotonic sodium chloride solution (1 mL) and intraperitoneal isotonic sodium chloride solution (80 mL)